Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden

Oncogene

Volumn 30, Issue 12, 2011, Pages 1402-1412

  Connelly, L ^a,b   Barham, W ^a   Onishko, H M ^a   Sherrill, T ^c   Chodosh, L A ^d   Blackwell, T S ^a,c,e   Yull, F E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

apoptosis; mammary; NF B; proliferation; tumorigenesis

Indexed keywords

CYCLIN D1; DOXYCYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; THYMOQUINONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; LUNG METASTASIS; MOUSE; NONHUMAN; ONCOGENE; POSTNATAL DEVELOPMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOXYCYCLINE; EPITHELIUM; FEMALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; NF-KAPPA B; TUMOR BURDEN;

MUS;

EID: 79953064635     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.521     Document Type: Article

References (38)

1. Baeuerle PA, Baltimore D. (1988). I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242: 540-546. (Pubitemid 18263193)
2. Baldwin Jr AS. (1996). The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683. (Pubitemid 26130197)
3. Basseres DS, Ebbs A, Levantini E, Baldwin AS. (2010). Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res 70: 3537-3546.
4. Baud V, Karin M. (2009). Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40.
5. Biswas DK, Iglehart JD. (2006). Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 209: 645-652. (Pubitemid 44665682)
6. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB et al. (2004). NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101: 10137-10142. (Pubitemid 38891208)
7. Bond M, Fabunmi RP, Baker AH, Newby AC. (1998). Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 435: 29-34. (Pubitemid 28432009)
8. Brantley DM, Chen CL, Muraoka RS, Bushdid PB, Bradberry JL, Kittrell F et al. (2001). Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol Biol Cell 12: 1445-1455. (Pubitemid 33044423)
9. Cao Y, Karin M. (2003). NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 8: 215-223. (Pubitemid 38129943)
10. Cao Y, Luo JL, Karin M. (2007). IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA 104: 15852-15857. (Pubitemid 350035388)
11. Cheng DS, Han W, Chen SM, Sherrill TP, Chont M, Park GY et al. (2007). Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway. J Immunol 178: 6504-6513. (Pubitemid 46717434)
12. Connelly L, Barham W, Pigg R, Saint-Jean L, Sherrill T, Cheng DS et al. (2010). Activation of nuclear factor kappa B in mammary epithelium promotes milk loss during mammary development and infection. J Cell Physiol 222: 73-81.
13. Connelly L, Robinson-Benion C, Chont M, Saint-Jean L, Li H, Polosukhin VV et al. (2007). A transgenic model reveals important roles for the NF-kappa B alternative pathway (p100/p52) in mammary development and links to tumorigenesis. J Biol Chem 282: 10028-10035. (Pubitemid 47104643)
14. Cude K, Wang Y, Choi HJ, Hsuan SL, Zhang H, Wang CY et al. (2007). Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell Biol 177: 253-264. (Pubitemid 46658637)
15. Everhart MB, Han W, Sherrill TP, Arutiunov M, Polosukhin VV, Burke JR et al. (2006). Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J Immunol 176: 4995-5005.
16. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. (2004). Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145: 5439-5447. (Pubitemid 39564581)
17. Ghosh S, May MJ, Kopp EB. (1998). NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260. (Pubitemid 28183365)
18. Gunther EJ, Belka GK, Wertheim GB, Wang J, Hartman JL, Boxer RB et al. (2002). A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J 16: 283-292. (Pubitemid 34195290)
19. Han YP, Tuan TL, Wu H, Hughes M, Garner WL. (2001). TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci 114: 131-139. (Pubitemid 32118063)
20. Hayden MS, Ghosh S. (2008). Shared principles in NF-kappaB signaling. Cell 132: 344-362.
21. Hennighausen L, Robinson GW. (2005). Information networks in the mammary gland. Nat Rev Mol Cell Biol 6: 715-725. (Pubitemid 41742795)
22. Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H. (2010). Thymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and in vivo. J Exp Clin Cancer Res 29: 87.
23. Karin M, Ben-Neriah Y. (2000). Phosphorylation meets ubiquitina-tion: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663. (Pubitemid 30365393)
24. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ et al. (2003). Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163: 2113-2126. (Pubitemid 37310040)
25. Liu M, Ju X, Willmarth NE, Casimiro MC, Ojeifo J, Sakamaki T et al. (2009). Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo. Am J Pathol 174: 1910-1920.
26. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C et al. (2009). Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462: 104-107.
27. Mistry P, Deacon K, Mistry S, Blank J, Patel R. (2004). NF-kappaB promotes survival during mitotic cell cycle arrest. J Biol Chem 279: 1482-1490. (Pubitemid 38082677)
28. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW. (1997). Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639. (Pubitemid 27281838)
29. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S et al. (2000). Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19: 4159-4169.
30. Pratt MA, Tibbo E, Robertson SJ, Jansson D, Hurst K, Perez-Iratxeta C et al. (2009). The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene 28: 2710-2722.
31. Roy PG, Thompson AM. (2006). Cyclin D1 and breast cancer. Breast 15: 718-727. (Pubitemid 44774238)
32. Sethi G, Ahn KS, Aggarwal BB. (2008). Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res 6: 1059-1070.
33. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD et al. (2007). Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 6: 1973-1982. (Pubitemid 47052487)
34. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM et al. (1997). Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952-2960. (Pubitemid 28022831)
35. Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV et al. (2007). Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci USA 104: 18514-18519. (Pubitemid 350210728)
36. Tapia MA, Gonzalez-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M et al. (2007). Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 6: 2284-2292. (Pubitemid 47547707)
37. Vallabhapurapu S, Karin M. (2009). Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27: 693-733.
38. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669-671. (Pubitemid 24199473)